News

Collaboration also includes UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Oxford BioMedica

Offering a professional training and development day aimed at improving performance and real world results, companies that support their teams through the all new PharmaTimes Sales Awards will, by demonstrating a desire to encourage learning and development, attract new talent to their organisation and create affiliate pride. “Shining a light on the professionalism of your team, overall success in the competition will also impact positively on your brand and its position in the marketplace,” says PharmaTimes business manager and competition lead Luci Sargood.

For the first time ever, the Communications Team of the Year competition will give individuals in agencies and pharma companies the chance to compete side by side.

PharmaTimes talks to Jayne Packham, managing director of the Jayne Packham Consultancy and lead judge for the Medical Information categories, about the importance of the new, PharmaTimes Medical & Scientific Excellence Awards.

RG6042 could be the first therapy targeting the underlying cause of the disease

RG6042 could be the first therapy targeting the underlying cause of the disease

Selumetinib is a MEK 1/2 inhibitor for the rare disease

The deal comprises the brands Aczone, Tazorac, Azelex, Cordran Tape and SeysaraTM

Overall revenues were at $4.7 billion, down 18% from the prior year period

PharmaTimes talks to Sabina Syed, managing director, Visions4Health and co-chair of the Marketer of the Year steering group about the importance of the competition against an ever changing landscape.

Only 14% of MPs and 16% of MEPs believe the sector takes priority in negotiations, but both want a greater understanding of pharma’s needs

Next phase of business continuity plan will launch 1 October at the latest as Agency faces higher-than-expected staff losses

Aegerion Pharmaceuticals Myalepta approved by EC

Drug becomes the first oral therapy and Janus kinase (JAK) inhibitor available for UC

Prescription drug sales were $7.1 billion for the first half of the year